Treeline Biosciences announced plans to go public through a reverse merger with Standard BioTools, creating a combined company expected to trade on the Nasdaq under the Treeline name. The deal structure is designed to provide Treeline with cash runway into 2029, supporting continued development of its early-stage oncology pipeline. The merged entity is expected to hold nearly $900 million in cash, and Treeline will bring a trio of disclosed experimental programs into public view. The company’s strategy emphasizes cancer target degradation and inhibition approaches, with multiple candidates already in early clinical testing. Standard BioTools shareholders will hold a minority stake post-close, while Treeline’s investors will take the majority—an ownership mix that reflects Treeline’s pipeline-driven rationale for the transaction.